angiotensin IV raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-10-08. Anything still debated is marked as such rather than presented as settled.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
| Property | Value | Notes |
|---|---|---|
| Common name | Dihexa | Shorthand used in research literature and supplier catalogs. |
| CAS Registry Number | 1401708-83-5 | Identifier assigned to the synthetic peptide. |
| Molecular formula | C27H44N4O5 | Reported formula; verify with a certificate of analysis. |
| Appearance | White to off-white powder | Typical form for lyophilized research peptides. |
| Typical storage | −20 °C or below, desiccated | Common condition for peptide stability. |
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
A common issue with animal vaccination is that it interferes with immunological tests as both infection and vaccination can result in antibodies against an antigen being made. To solve this issue, special marker vaccines are created using pathogen strains carrying at least one epitope less than the equivalent wild microorganism. An accompanying diagnostic test that detects the antibody against that epitope assists in identifying whether the animal has been vaccinated or not. They are also called "DIVA vaccines". The first marker vaccines and companion diagnostic tests were developed by J. T. van Oirschot and colleagues at the Central Veterinary Institute in Lelystad, The Netherlands. They found that some existing vaccines against pseudorabies (also termed Aujeszky's disease) had deletions in their viral genome (among which was the gE gene). Monoclonal antibodies were produced against that deletion and selected to develop an ELISA that demonstrated antibodies against gE. In addition, novel genetically engineered gE-negative vaccines were constructed. Along the same lines, DIVA vaccines and companion diagnostic tests against bovine herpesvirus 1 infections have been developed. The DIVA strategy has been applied in various countries to successfully eradicate pseudorabies virus from those countries. Swine populations were intensively vaccinated and monitored by the companion diagnostic test and, subsequently, the infected pigs were removed from the population. Bovine herpesvirus 1 DIVA vaccines are widely used in European BoHV-1 control and eradication programmes.
Franklin's X-ray diffraction data for DNA and her systematic analysis of DNA's structural features were useful to Watson and Crick in guiding them towards a correct molecular model. The key problem for Watson and Crick, which could not be resolved by the data from King's College, was to guess how the nucleotide bases pack into the core of the DNA double helix.
Valve was named as a defendant in two lawsuits in June and July 2016 related to third-party gambling sites that use the Steamworks API to allow betting with the virtual currency of cosmetic weapon replacement textures, better known as "skins", from Counter-Strike: Global Offensive, which through these sites can be converted from or to real-world money. Both suits assert Valve aiding in underaged gambling. Valve subsequently stated it has no commercial ties with these sites, and that it would demand these sites cease their use of the Steamworks API as they violate the authorized use policies. In October 2016, the Washington State Gambling Commission required Valve to stop the use of virtual skins for gambling on Steam, stating they would face legal repercussions if they failed to co-operate. On October 17, 2016, Valve sent a letter to the Washington State Gambling Commission stating that it had "no business relationship with such gambling sites", asserting that they come into existence, operate, and go out of existence without its knowledge and consent, adding that it was not aware of any such law that Steam or any of its games were violating.
Though Zuckerkandl and Pauling saw the clock as compatible with natural selection, it would later become the basis of the neutral theory of molecular evolution, in which genetic drift rather than selection is the driving force of evolution at the molecular level.
CP, Crude protein; NRC MR, National Research Council Minimal Requirement; NR, not required (taurine not an essential amino acid in the dog); NA, not adequate sample for analysis Amino acids measured on a mg/g DM basis The results demonstrated that all evaluated insects met the canine and feline MR for growth of the NRC for EAA and CP with exception to the black soldier fly in regards to taurine, where composition was lower than recommended.
Sources: en.wikipedia.org
The Chipotlane acts as a drive-thru, but it is for mobile order pickup only; customers are unable to order food at the handout window but are welcome to pick up their mobile orders through the Chipotlane or inside the restaurant. As of 2023, there are over 500+ locations, which include the Chipotlane in order to make the restaurant run more efficiently. In June 2018, the company announced the closing of 65 under-performing restaurants. Ells broke all ties with the company in March 2020 by resigning as its chairman and departing from its board of directors. In January 2023, the company announced plans to hire 15,000 workers and expand to 7,000 locations, up from a previous goal of 6,000. This would double its footprint. At the time of the announcement, it had more than 100,000 employees. An article in The Wall Street Journal in July noted the chain would focus on opening 700–800 new locations in small towns and cities as part of its plan to expand by nearly 3,800 locations in territory traditionally dominated by chains like McDonald's and Applebee's. In 2023 Chipotle saw $9.9 billion in revenue with 14.3% growth year on year and $3 million in average unit volumes (per restaurant revenue) and 7.9% growth in comparable sales; in 2023, 37.4% of their revenue came via online orders, third-party delivery services or their new Chipotlanes. In September 2024, Chipotle announced it was collaborating with Vebu, a company that develops automation and robotics equipment for the food industry, on a new automated avocado processing machine, Autocado.
=== Research === Baeocystin (PLZ-1019) – non-hallucinogenic serotonin 5-HT2A receptor agonist, other actions Norpsilocin (PLZ-1017) – non-hallucinogenic serotonin 5-HT2A receptor agonist, other actions Roluperidone (CYR-101, MIN-101, MT-210) – serotonin 5-HT2A, sigma σ2, and α1A-adrenergic receptor antagonist Squalamine (ENT-01; Enterin-01; kenterin) – various actions
== Function in medicine == Arenobufagin has been widely used in traditional Chinese medicine (TCM) to attempt to treat carcinogenesis, since it inhibits cell growth in several cancer cells. It is one of the central active ingredients of toad toxin for this treatment. This happens both in purified form or in combination with other ingredients, which are mostly herbal components. Toad toxin is in fact still used in clinical practice in TCM to treat hepatocellular carcinoma (HCC). So far there is still little known about the anti-angiogenic properties of Arenobufagin. One study shows that Arenobufagin inhibits VEGF-induced endothial cell tube formation.
== Diagnosis == Substance use disorders can be confused with other psychiatric disorders. There are diagnoses for substance-induced mood disorders and substance-induced anxiety disorders and thus such overlap can be complicated. For this reason, the DSM-IV advises that diagnoses of primary psychiatric disorders not be made in the absence of sobriety (of a duration sufficient to allow for any substance-induced post-acute-withdrawal symptoms to dissipate) up to 1 year.
=== South Africa === The species has been protected in South Africa since 1991; with laws banning both deliberate killing and selling. In the province of KwaZulu-Natal (KZN), the KwaZulu-Natal Sharks Board employs nets around protected beaches to mitigate the risk of shark attacks, though these are excluded from major aggregation sites. Population estimates have varied: a 1996 study estimated an average of 1,279 individuals between 1989 and 1993, while a 2004 study suggested the population had grown to 1,953 post-protection. A 2023 study concluded that white shark numbers off South Africa have remained stable since 1991, despite declines in sightings at Western Cape. Researchers suggested the population may be shifting eastward, potentially in response to orca predation. However, these findings are disputed; in 2024, it was noted that white shark catches in KZN have actually declined since 2010, casting doubt on the theory of an eastward migration.
Sources: en.wikipedia.org
Coronary artery disease, leading to angina or myocardial infarction ("heart attack") Diabetic myonecrosis ('muscle wasting') Peripheral vascular disease, which contributes to intermittent claudication (exertion-related leg and foot pain) as well as diabetic foot. Stroke (mainly the ischemic type) Carotid artery stenosis does not occur more often in diabetes, and there appears to be a lower prevalence of abdominal aortic aneurysm. However, diabetes does cause higher morbidity, mortality and operative risks with these conditions. Diabetic foot, often due to a combination of sensory neuropathy (numbness or insensitivity) and vascular damage, increases rates of skin ulcers (diabetic foot ulcers) and infection and, in serious cases, necrosis and gangrene. It is why it takes longer for diabetics to heal from leg and foot wounds and why diabetics are prone to leg and foot infections. In the developed world it is the most common cause of non-traumatic adult amputation, usually of toes and/or feet. Female infertility is more common in women with diabetes type 1, despite modern treatment, also delayed puberty and menarche, menstrual irregularities (especially oligomenorrhoea), mild hyperandrogenism, polycystic ovarian syndrome, fewer live born children and possibly earlier menopause. Animal models indicate that on the molecular level diabetes causes defective leptin, insulin and kisspeptin signalling.
The neuromedin U receptors are two G-protein coupled receptors which bind the neuropeptide hormones neuromedin U and neuromedin S. There are two subtypes of the neuromedin U receptor, each encoded by a separate gene (NMUR1, NMUR2).
== Taxonomy == The species was first described in 1906 as Stropharia cubensis by American mycologist Franklin Sumner Earle in Cuba. In 1907, it was identified as Naematoloma caerulescens in Tonkin (now Vietnam) by French pharmacist and mycologist Narcisse Théophile Patouillard, while in 1941, it was called Stropharia cyanescens by William Alphonso Murrill near Gainesville in Florida. German-born mycologist Rolf Singer moved the species into the genus Psilocybe in 1949, giving it the binomial name Psilocybe cubensis. The synonyms were later also assigned to the species Psilocybe cubensis. The name Psilocybe is derived from the Ancient Greek roots psilos (ψιλος) and kubê (κυβη), and translates as "bare head". Cubensis means "coming from Cuba", and refers to the type locality published by Earle. Singer divided P. cubensis into three varieties: the nominate, which usually had a brownish cap, Murrill's cyanescens from Florida, which generally had a pale cap, and var caerulascens from Indochina with a more yellowish cap. Psilocybe cubensis is commonly known as gold top, golden top or gold cap in Australia, sacred mushroom or blue mushroom in Brazil, and San Ysidro or Palenque mushroom in the United States and Mexico, while the term "magic mushroom" has been applied to hallucinogenic mushrooms in general. It is commonly known as "Golden teacher" in South Africa. A common name in Thai is "Hed keequai", which translates as "mushroom which appears after water buffalo defecates". Between 2013 and 2022, several samples of an unknown species of Psilocybe mushroom were collected.
==== Employees and DuPont exposed community ==== In 2010, the three members of the C8 Science Panel published a review of the epidemiological evidence on PFOA exposure in Environmental Health Perspectives. Insufficient evidence exists to conclude PFOA causes adverse health effects in humans, but consistent evidence exists on associations with higher cholesterol and uric acid. Whether or not these potential effects result in an increase in cardiovascular disease is unknown. Further data on the 69,030 member cohort that is being studied by the panel is scheduled for release through 2012. A 2011 epidemiological study demonstrated "probable link" between PFOA and kidney cancer, testicular cancer, thyroid disease, high cholesterol, pre-eclampsia and ulcerative colitis. Facial birth defects, an effect observed in rat offspring, occurred with the children of two out of seven female DuPont employees from the Washington Works facility from 1979 to 1981. Bucky Bailey is one of the affected individuals; DuPont, however, does not accept any liability from the toxicity of PFOA. While 3M sent DuPont results from a study that showed birth defects to rats administered PFOA and DuPont moved the women out of the Teflon production unit, subsequent animal testing led DuPont to conclude there was no reproductive risk to women, and they were returned to the production unit. However, data released in March 2009 on the community around DuPont's Washington Works plant showed "a modest, imprecise indication of an elevation in risk ... above the 90th percentile ...
Sources: en.wikipedia.org
Dihexa is a synthetic peptide modeled on angiotensin IV. It is used in laboratory and animal research, not as an approved medicine. Human effects remain poorly characterized.
It is produced by chemical synthesis, not extracted from plants or animals. Its design is based on a naturally occurring peptide fragment. Suppliers sell it as a research chemical.
No, dihexa is a modified analog of angiotensin IV. The two share a structural relationship but differ in chemical details. Research on one does not automatically apply to the other.
Dihexa is a synthetic peptide-like compound studied primarily in preclinical models. It is often classified as an angiotensin IV analog and has been investigated for effects on neuronal connectivity. It is not an approved drug or dietary supplement.